As the world longs for a return to normal life after more than a year of pandemic experience, countries are racing to deliver vaccines that should slow – and hopefully stop – the spread of the coronavirus.
Doing so successfully will depend on a number of factors, the production and transport of billions of doses, the assurance that rich nations do not monopolize the world supply of vaccines, and most importantly, the actual delivery of doses into people’s arms.
The charts and maps below will be updated to show the latest data on the largest introduction of vaccinations in history, in the United States and around the world.
There are notable state-to-state differences in how quickly vaccines are given to people.
The first two vaccines approved for emergency use in the United States, developed by Pfizer / BioNTech and Moderna companies, are designed to be given in two doses several weeks apart. The Johnson & Johnson vaccine licensed for use in late February requires only one dose. So vaccinating everyone in the United States will ultimately mean giving somewhere between 100 and 200 doses per 100 people in every state and territory – or a total of between 330 and 660 million doses for the entire nation. It is a huge logistical challenge.
The launch of the vaccine in the United States has started slower than expected. The Trump administration has set a target of providing 20 million vaccinations by the end of 2020. That target was not met until the end of January. In early March, President Joe Biden said the United States would have enough vaccines for all adults by the end of May, two months earlier than his administration previously planned. However, there are concerns that the vaccination campaign is leaving the poorest people and communities of color behind.
Search or browse this table to find out how your state or territory is doing on these key vaccine launch measures.
Vaccine launch history
This graph shows the number of vaccines administered per 100 people for each state since the beginning of 2021. The top three states and the national numbers of the United States are highlighted. Type the name of any other US state or territory in the search bar and select to add it to the chart.
This graph shows the daily number of vaccine doses administered to people across the nation since early 2021. Due to the spikes in data due to reporting delays, the line showing the 7-day moving average of doses administered gives a clearer idea of whether implementation is speeding up or slowing down.
Introduction of the vaccine by country
More countries appear on this map showing vaccine doses given per 100 people because these numbers are reported more widely.
The United States is ahead of most other nations in introducing the vaccine. But among the main nations Israel was the first leader.
Search or browse this table to see how each country is doing. It reveals that some nations have adopted different strategies: the UK, for example, has decided to give as many people a starting dose as possible, delaying their second shots.
Vaccine launch history
This graph shows the number of vaccines given per 100 people for each country since the beginning of 2021. Type the name of any country in the search bar and select to compare its timeline with the United States and the other three main countries they lead the implementation of the vaccine around the world. Only countries that have started their vaccination campaigns will appear.
This graph shows the reported daily number of vaccine doses given to people around the world. Due to spikes due to reporting delays, the line showing the 7-day moving average of delivered doses gives a clearer idea of whether implementation is speeding up or slowing down.
Status of the main vaccines
This table documents the status of major COVID-19 vaccines, showing authorizations for use in the United States and other selected markets, as well as pricing from information on UNICEF-filled purchasing agreements, where available.
Pfizer / BioNTech and Moderna’s vaccines, with clinical trial results indicating they are over 90% effective in preventing disease, are based on new technology that delivers an RNA sequence that causes our cells to make proteins. Viral, triggering an immune response.
The downside is that these vaccines are more expensive than those made by combining genetic material from the coronavirus with a disabled version of another virus, such as those produced by the Anglo-Swedish company AstraZeneca, based on research from the University of Oxford, Johnson & Johnson. , and the Gamaleya Research Institute of Russia.
Other leading vaccines rely on inactivated versions of the coronavirus, a long-standing approach to producing vaccines or protein subunits of the virus.
Jeremy Singer-Vine helped bring this story back.